(Q46544844)

English

Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study

scientific article published in May 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18547902

Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18547902

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

abacavir/lamivudine

1 reference

based on heuristic

inferred from title

author name string

Richard Elion

1

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18547902

Edwin Dejesus

2

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18547902

Michael Sension

3

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18547902

Daniel Berger

4

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18547902

William Towner

5

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18547902

Gary Richmond

6

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18547902

Marty St Clair

7

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18547902

Linda Yau

8

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18547902

Belinda Ha

9

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18547902

COL102060 Study Team

10

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18547902

publication date

1 May 2008

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18547902

HIV Clinical Trials

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18547902

9

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18547902

3

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18547902

152-163

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18547902

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures

1 reference

https://api.crossref.org/works/10.1310%2FHCT0903-152

21 January 2018

96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures

1 reference

https://api.crossref.org/works/10.1310%2FHCT0903-152

21 January 2018

Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study

1 reference

https://api.crossref.org/works/10.1310%2FHCT0903-152

21 January 2018

Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study

1 reference

https://api.crossref.org/works/10.1310%2FHCT0903-152

21 January 2018

Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine

1 reference

https://api.crossref.org/works/10.1310%2FHCT0903-152

21 January 2018

Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study

1 reference

https://api.crossref.org/works/10.1310%2FHCT0903-152

21 January 2018

Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel

1 reference

https://api.crossref.org/works/10.1310%2FHCT0903-152

21 January 2018

Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate

1 reference

https://api.crossref.org/works/10.1310%2FHCT0903-152

21 January 2018

Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.

1 reference

https://api.crossref.org/works/10.1310%2FHCT0903-152

21 January 2018

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1310%2FHCT0903-152

21 January 2018

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

1 reference

https://api.crossref.org/works/10.1310%2FHCT0903-152

21 January 2018

Insulin resistance in HIV-infected men and women in the nutrition for healthy living cohort

1 reference

https://api.crossref.org/works/10.1310%2FHCT0903-152

21 January 2018

Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients

1 reference

https://api.crossref.org/works/10.1310%2FHCT0903-152

21 January 2018

Low-density lipoprotein particle number and risk for cardiovascular disease

1 reference

https://api.crossref.org/works/10.1310%2FHCT0903-152

21 January 2018

Measurement issues related to lipoprotein heterogeneity

1 reference

https://api.crossref.org/works/10.1310%2FHCT0903-152

21 January 2018

Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations

1 reference

https://api.crossref.org/works/10.1310%2FHCT0903-152

21 January 2018

Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study

1 reference

https://api.crossref.org/works/10.1310%2FHCT0903-152

21 January 2018

HLA-B*5701 screening for hypersensitivity to abacavir

1 reference

https://api.crossref.org/works/10.1310%2FHCT0903-152

21 January 2018

Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the

1 reference

https://api.crossref.org/works/10.1310%2FHCT0903-152

21 January 2018

Identifiers

10.1310/HCT0903-152

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18547902

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/18547902

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46544844&oldid=2117448397"